Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020
Biological and Pharmaceutical Bulletin · 2023
DOI: 10.1248/bpb.b23-00149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Toshiyuki Shizuya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Social Pharmacy and Regulatory Science, Showa Pharmaceutical University. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Social Pharmacy and Regulatory Science, Showa Pharmaceutical University.
- Japan Development, MSD K.K.
Zitieren
APA
Shizuya, T., & Miyazaki, S. (2023). Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b23-00149
Vancouver
Shizuya T, Miyazaki S. Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b23-00149
BibTeX
@article{Shizuya2023,
author = {Shizuya, Toshiyuki and Miyazaki, Seiko},
title = {Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020},
journal = {Biological and Pharmaceutical Bulletin},
year = {2023},
doi = {10.1248/bpb.b23-00149}
}
EUVIMED